124 related articles for article (PubMed ID: 19336653)
1. Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma.
Bryant ML; Worthington MA; Parsons K
Ann Pharmacother; 2009 Apr; 43(4):714-20. PubMed ID: 19336653
[TBL] [Abstract][Full Text] [Related]
2. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons.
Clay PG; Voss LE; Williams C; Daume EC
Ann Pharmacother; 2008 May; 42(5):670-9. PubMed ID: 18413693
[TBL] [Abstract][Full Text] [Related]
3. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of osteoporosis and osteopenia in children--own experience].
Chlebna-Sokół D; Błaszczyk A; Rusińska A; Loba-Jakubowska E
Przegl Lek; 2003; 60(1):5-11. PubMed ID: 12884638
[TBL] [Abstract][Full Text] [Related]
5. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.
Athanassiadou F; Tragiannidis A; Rousso I; Katsos G; Sidi V; Koliouskas D; Papastergiou C; Tsituridis I
Pediatr Hematol Oncol; 2005 Jun; 22(4):285-9. PubMed ID: 16020115
[TBL] [Abstract][Full Text] [Related]
7. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
8. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.
Amin S; LaValley MP; Simms RW; Felson DT
Arthritis Rheum; 1999 Aug; 42(8):1740-51. PubMed ID: 10446876
[TBL] [Abstract][Full Text] [Related]
9. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.
Amin S; Lavalley MP; Simms RW; Felson DT
J Bone Miner Res; 2002 Aug; 17(8):1512-26. PubMed ID: 12162505
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.
CMAJ; 1996 Oct; 155(8):1113-33. PubMed ID: 8873639
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience.
Lethaby C; Wiernikowski J; Sala A; Naronha M; Webber C; Barr RD
J Pediatr Hematol Oncol; 2007 Sep; 29(9):613-6. PubMed ID: 17805035
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
Bianchi ML; Cimaz R; Bardare M; Zulian F; Lepore L; Boncompagni A; Galbiati E; Corona F; Luisetto G; Giuntini D; Picco P; Brandi ML; Falcini F
Arthritis Rheum; 2000 Sep; 43(9):1960-6. PubMed ID: 11014345
[TBL] [Abstract][Full Text] [Related]
13. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
15. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia.
Pickard AS; Topfer LA; Feeny DH
J Natl Cancer Inst Monogr; 2004; (33):102-25. PubMed ID: 15504922
[TBL] [Abstract][Full Text] [Related]
16. [Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors].
Von Tirpitz C; Pischulti G; Klaus J; Rieber A; Brückel J; Böhm BO; Adler G; Reinshagen M
Z Gastroenterol; 1999 Jan; 37(1):5-12. PubMed ID: 10091278
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy.
Selimoglu MA; Ertekin V; Doneray H; Yildirim M
J Clin Gastroenterol; 2008 Feb; 42(2):194-8. PubMed ID: 18209591
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
Migliorati CA; Schubert MM; Peterson DE; Seneda LM
Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
[TBL] [Abstract][Full Text] [Related]
20. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
